Compare Merck & Co., Inc. (MRK) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Western Union Co — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Western Union Co trades at $6.95 (market cap $2.18B). The key difference: Merck & Co., Inc. is far larger — about 168× Western Union Co's market cap, and Western Union Co pays the higher dividend (13.43%). Which is the better fit depends on your goals.
| MRK | WU | |
|---|---|---|
Market Cap | $366.28B | $2.18B |
Sector | Health | Technology |
52-Week High | $156.43 | $10.28 |
52-Week Low | $77.60 | $6.36 |
Enterprise Value | $413.04B | $2.09B |
Dividend Yield | 2.29% | 13.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Western Union (WU) trades at $7.00, down 2.51% on the day, reflecting a bearish technical trend and mixed earnings performance with recent quarterly misses. Valuation metrics appear attractive with a P/E of 5.65 and P/S of 0.55, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company is pursuing a $200 million cost-saving plan by 2027 and expanding its retail footprint through partnerships like Total Wireless, while its pending acquisition of Intermex faces regulatory scrutiny.
The outlook is cautious due to declining revenue, integration risks from the Intermex deal, and a high dividend yield that some analysts view as unsustainable. Near-term catalysts include regulatory approvals for the acquisition and execution of cost-cutting initiatives, but competitive pressures and margin compression pose significant risks to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
